HBM Holdings Limited announced that, the Company has completed its first interim analysis of phase III clinical trial in China of tanfanercept (HBM9036), a new global innovative tumor necrosis factor (TNF) receptor-1 fragment-based drug for adult patients with moderate-to-severe dry eye disease (DED). The trial was planned to enroll 674 patients and to conduct two interim analyses over the course of the trial. As of 28 December 2021, a total number of 187 patients have been evaluated for key efficacy endpoints assessment.

The first interim analysis was performed according to trial protocol, and the interim data were reviewed by the Independent Data Monitoring Committee (the "IDMC"). As a result of its observed efficacy trend and favorable safety, the study was recommended by the IDMC to be continued according to the current protocol. As of the date of this announcement, the Company remains blinded to whether the participants involved in the trial received drug or placebo.

Further announcement(s) regarding the details and developments of the phase III clinical trial will be made by the Company as and when appropriate.